JAMA Editors' Summary

Subcutaneous Tirzepatide for Type 2 Diabetes, Noninvasive Respiratory Strategies for COVID-19 and Acute Hypoxemic Respiratory Failure, Clinical Outcomes 1 Year After ICU Treatment for COVID-19, and more

Feb 8, 2022
Ask episode
Chapters
Transcript
Episode notes